PRPH · ProPhase Labs, Inc.
$0.03
-0.01 (-25.00%)
At close · Aug 17
Going-concern doubt
— flagged Jun 30, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s plans do not alleviate this substantial doubt.”View the 10-Q filed Jun 30, 2026
Market Cap
$560,641
Shares
14.02M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4.35M
-35.8%
FY2025
Net Income
-$14.74M
+72.4%
FY2025
Gross Margin
31.85%
+34.1pp
FY2025
Operating Margin
-415.35%
+155.2pp
FY2025
Diluted EPS
-$1.74
+93.5%
FY2025
Operating Cash Flow
-$8.34M
+52.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.08M | $4.35M | $6.77M | $34.98M | $122.65M | $79.04M | $14.51M | $9.88M | $13.13M | $9.87M | $4.21M | $2.52M | $22.07M | $25.03M | $22.41M | $17.45M | $14.5M | $19.82M | |
| — | — | — | — | — | — | — | — | $167K | $327K | -$212K | -$16K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $11K | — | |
| $2.93M | $2.96M | $6.92M | $19.43M | $51.99M | $37.05M | $9.91M | $7.26M | $8.35M | $7.92M | $3.21M | $1.69M | $7.89M | $8.36M | $8.15M | $6.17M | $5.67M | $8.25M | |
| $1.15M | $1.38M | -$150K | $15.56M | $70.65M | $41.99M | $4.61M | $2.62M | $4.78M | $1.95M | $997K | $832K | $14.18M | $16.67M | $14.25M | $11.28M | $8.83M | $11.57M | |
| — | 31.85% | -2.22% | 44.47% | 57.61% | 53.12% | 31.73% | 26.48% | 36.42% | 19.74% | 23.7% | 33.04% | 64.25% | 66.6% | 63.61% | 64.64% | 60.89% | 58.38% | |
| — | $107K | $594K | $1.4M | $652K | $520K | $633K | $332K | $398K | $431K | $358K | $340K | $1.32M | $824K | $1.3M | $1.09M | $794K | $1.31M | |
| — | — | — | — | — | — | $1.29M | $1.04M | $1.11M | $699K | $1.7M | $303K | $8.97M | $9.54M | $8.95M | $7.9M | $5.58M | $4.85M | |
| $17.95M | $19.32M | $37.89M | $33.44M | $34.39M | $22.49M | $7.5M | $4.48M | $4.91M | $4.81M | $2.73M | $2.27M | $8.14M | $5.89M | $6.13M | $5.03M | $6.05M | $9.34M | |
| $2.6M | $2.6M | $2.6M | $2.9M | $2.4M | $1.4M | $73K | — | — | — | — | — | — | — | — | — | — | — | |
| $4.31M | $4.83M | $6.19M | $6.05M | $4.72M | $3.23M | $449K | $398K | $383K | $337K | $426K | $367K | $277K | $243K | $252K | $355K | $363K | $522K | |
| $17.96M | $19.43M | $38.48M | $36.78M | $47.06M | $32.19M | $8.58M | $5.85M | $6.42M | $5.94M | $4.79M | $2.91M | $22.01M | $16.26M | $15.35M | $14.02M | $12.42M | $15.5M | |
| -$16.81M | -$18.05M | -$38.63M | -$21.22M | $23.6M | $9.8M | -$2.08M | -$3.24M | -$1.63M | -$3.99M | -$2.66M | -$3.58M | -$7.83M | $416K | -$1.1M | -$2.74M | -$3.59M | -$3.94M | |
| — | -415.35% | -570.59% | -60.66% | 19.24% | 12.4% | -14.34% | -32.8% | -12.45% | -40.44% | -63.15% | -142.34% | -35.47% | 1.66% | -4.9% | -15.69% | -24.78% | -19.86% | |
| -$12.5M | -$13.22M | -$32.44M | -$15.17M | $28.31M | $13.04M | -$1.63M | -$2.84M | -$1.25M | -$3.65M | -$2.23M | -$3.22M | -$7.55M | $659K | -$846K | -$2.38M | -$3.23M | -$3.41M | |
| $7.05M | $6.93M | $3.35M | $1.28M | $764K | $1.15M | $295K | — | — | $54K | $213K | $18K | $10K | $13K | $0 | $0 | — | — | |
| — | — | — | — | $153K | $642K | $62K | $133K | $167K | — | — | — | — | — | — | — | — | — | |
| -$258K | -$174K | -$18K | $10K | $0 | — | — | — | — | $54K | $187K | $11K | — | — | — | — | — | — | |
| — | — | $91K | $23K | $127K | — | $1.89M | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$166K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $0 | -$76K | -$240K | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$22.51M | -$23.39M | -$42.33M | -$22.4M | $22.91M | $5.31M | -$2.31M | -$3.11M | -$1.47M | -$3.66M | -$4.01M | -$2.09M | -$7.83M | $405K | -$1.09M | -$2.71M | -$3.54M | -$3.93M | |
| $1.37M | $0 | $7.2M | -$6.02M | $4.45M | -$968K | $12K | — | $103K | -$1.42M | — | — | $0 | $0 | $0 | $0 | -$40K | -$84K | |
| -$23.88M | -$14.74M | -$53.36M | -$16.78M | $18.46M | $6.27M | -$2.13M | -$3.15M | -$1.74M | $40.59M | -$2.87M | -$3.6M | -$7.83M | $405K | -$1.09M | -$2.71M | -$3.5M | -$3.84M | |
| — | -339.31% | -788.24% | -47.97% | 15.05% | 7.94% | -14.64% | -31.86% | -13.26% | 411.36% | -68.19% | -142.97% | -35.5% | 1.62% | -4.87% | -15.53% | -24.14% | -19.39% | |
| -$23.6M | — | — | -$16.78M | $18.46M | $6.27M | -$2.13M | — | — | — | — | -$3.6M | -$7.83M | $405K | -$1.09M | -$2.71M | -$3.5M | — | |
| — | -$14.74M | -$53.26M | -$17.84M | $19.4M | $6.11M | -$2.13M | -$3.12M | -$1.69M | $40.51M | -$2.87M | -$3.6M | — | — | — | — | — | — | |
| USD/shares | — | -$1.74 | -$26.68 | -$9.80 | $11.70 | $4.10 | -$1.80 | -$2.70 | -$1.50 | $26.10 | -$1.70 | -$2.20 | -$4.70 | $0.30 | -$0.70 | -$1.80 | $2.50 | — |
| USD/shares | — | -$1.74 | -$26.68 | -$9.80 | $10.20 | $4.00 | -$1.80 | — | -$1.50 | $25.90 | -$1.70 | -$2.20 | -$4.70 | $0.30 | -$0.70 | -$1.80 | $2.50 | — |
| shares | — | 8.49M | 2M | 1.72M | 1.58M | 1.52M | 1.16M | 1.16M | 1.14M | 1.56M | 1.71M | 1.64M | 1677.3 | 1583.9 | 1.48M | 1.48M | 1428.5 | — |
| shares | — | 8.49M | 2M | 1.72M | 1.87M | 1.84M | 1.16M | 1.16M | 1.14M | 1.57M | 1.71M | 1.64M | 1677.3 | 1627.6 | 1.48M | 1.48M | 1428.5 | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2024: $19.94M in buybacks, $34.32M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Diagnostics & Research median 3.25×
EV/EBIT
—
Diagnostics & Research median 31.43×
P/E (TTM)
—
Diagnostics & Research median 31.99×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Consumer Products | $4,345,000 | $6,770,000 | $10,135,000 | $14,318,000 | $10,483,000 | $13,237,000 |
| Diagnostic Services | $0 | $0 | $24,849,000 | $108,329,000 | $68,559,000 | $1,277,000 |